Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases, announced that President and CEO Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13. The presentation will focus on the scientific basis for treating Alzheimer’s disease as a multi-protein disorder and will highlight Annovis’ approach of targeting multiple neurotoxic proteins simultaneously through its lead drug candidate, buntanetap, which is currently in a pivotal Phase 3 clinical trial.
The company’s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. This multi-protein approach is particularly significant because Alzheimer’s disease involves several toxic proteins, and targeting just one may not be sufficient to stop the disease.
The presentation at Fierce Biotech Week, a major industry event, underscores the growing interest in therapies that address multiple pathways in neurodegenerative diseases. For leaders in business and technology, this news matters because it highlights a paradigm shift in drug development: moving from single-target therapies to multi-target strategies that could offer more effective treatments for complex conditions like Alzheimer’s. If successful, buntanetap could become a cornerstone therapy, potentially reducing the economic burden of Alzheimer’s, which is estimated to cost over $1 trillion annually worldwide.
Annovis Bio (NYSE: ANVS) is headquartered in Malvern, Pennsylvania, and is focused on developing treatments for Alzheimer’s disease (AD) and Parkinson’s disease (PD). The company’s lead candidate, buntanetap, is designed to inhibit the translation of multiple neurotoxic proteins, which could slow or halt disease progression. The Phase 3 trial is a critical step toward regulatory approval, and positive results could transform the treatment landscape for millions of patients.
For investors and industry observers, the presentation at Fierce Biotech Week provides an opportunity to hear directly from the CEO about the scientific rationale and clinical progress. The event also serves as a platform to engage with key stakeholders in the biotech and pharmaceutical sectors. More information about Annovis and its pipeline can be found on its website at www.annovisbio.com. The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.
The implications of this announcement are far-reaching. For the biotech industry, it reinforces the importance of multi-target approaches in tackling complex diseases. For patients and caregivers, it offers hope for a more effective treatment that could address the root causes of Alzheimer’s rather than just symptoms. For investors, it signals potential upside if buntanetap succeeds in Phase 3, given the large unmet need in Alzheimer’s therapy. As the population ages, the demand for effective treatments will only grow, making advances in this area critical for public health and economic stability.
